The textbook on Lung Cancer: time for personalized medicine

Posted On 2015-04-02 15:58:03

We are glad to announce that the book Lung Cancer is accomplished and launched recently by the AME Publishing Company (Figure 1).


















Figure 1. The book Lung Cancer is launched by the AME Publishing Company

At the 3rd Asian Single Port VATS Symposium & Live Surgery held on March 26-27 in Hong Kong, an announcement ceremony for the book on Lung Cancer was held (Figure 2). In its debut, we are glad to see the book well received by the international experts.













Figure 2. The book on Lung Cancer was launched in the 3rd Asian Single Port VATS Symposium & Live Surgery with the recognition of the world known experts (from right to left): Prof. Alan Sihoe, Prof. Jianxing He, Prof. Jheon Sanghoon, Prof. Thomas D’Amico, Prof. Calvin Ng, Prof. Keneng Chen.

Our Honorary Editors-in Chief for Lung Cancer are Prof. Jie He and Prof. Rafael Rosell and the Editors-in Chief are Prof. Jianxing He, Prof. Thomas A. D’Amico and Prof. Xiuyi Zhi. The Associate Editors-in Chief include Prof. Qun Wang, Prof. Tristan D. Yan, Prof. Calvin Ng, Prof. Caicun Zhou, Prof. Heather A. Wakelee, Dr. Wenhua Liang.

Despite many years of dedicated effort, including basic, translational and clinical research, public education, and health care policy, lung cancer remains the number one cause of death by malignancy in the world, and it is responsible for as many deaths as colon, breast, pancreas and prostate cancers combined in the US. Thus, successful efforts to better understand and better treat lung cancer will have long lasting ramifications, for patient care specifically and for public health globally, as well.

The volume, Lung Cancer, is just such an effort. Comprised of contributions by the most accomplished scientists and clinicians internationally, Lung Cancer thoroughly examines the spectrum of topics related to better understanding and better treating the world’s most lethal malignancy.

From the basic science of lung cancer to the most advanced therapeutic techniques, this text provides the reader—student or professional—with a most comprehensive analysis. Lung Cancer also provides practical information epitomizing the rapid progress in the field of lung cancer today and instilling in physicians the confidence derived from this knowledge when dealing with patients.

We would like to express our gratitude to all the leading investigators who have contributed to this endeavor and to the growing knowledge of lung cancer today.

The book Lung Cancer is now available both online and in print with English and Chinese version. Please enjoy.

Table of Contents for Lung Cancer:

Table of Contents

Preface

Contributors

Pathology

1        Molecular biology of lung cancer

Wendy A. Cooper, David C. L. Lam, Sandra A. O’Toole, JohnD. Minna

16      The pivotal role of pathology in the management of lung cancer

Morgan R. Davidson, Adi F. Gazdar, Belinda E. Clarke

34      Towards optimal pathologic staging of resectable non-small celllung cancer

Raymond U. Osarogiagbon, Gail E. Darling

42      Molecular determinants of lung cancer metastasis to the centralnervous system

Timothy G. Whitsett, Landon J. Inge, Harshil D. Dhruv,Philip Y. Cheung, Glen J. Weiss, Ross M. Bremner, Jeffrey A. Winkles, Nhan L.Tran

53      Genetic susceptibility to lung cancer and co-morbidities

Ian A. Yang, John W. Holloway, Kwun M. Fong

64      Non-neuronal cholinergic system in airways and lung cancer susceptibility

Laura Saracino, Michele Zorzetto, Simona Inghilleri,Ernesto Pozzi, Giulia Maria Stella

Diagnosis

75      Diagnostic bronchoscopy--current and future perspectives

Steven Leong, Tawimas Shaipanich, Stephen Lam, KazuhiroYasufuku

90      Modern diagnostic and therapeutic interventional radiology in lung cancer

Wai-Kit Lee, Eddie W. F. Lau, Kwang Chin, OliverSedlaczek, Karin Steinke

105    Screening for lung cancer with low-dose computed tomography: are view of current status

Henry M. Marshall, Rayleen V. Bowman, Ian A. Yang, KwunM. Fong, Christine D. Berg

125    Exhaled breath analysis for lung cancer

Annette G. Dent, Tom G. Sutedja, Paul V. Zimmerman

138    Interventional pulmonology approaches in the diagnosis and treatment of early stage non small cell lung cancer

Ryu Peter Hambrook Tofts, Peter M. J. Lee, Arthur WaiSung

154    Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence

Sonja Sudarski, Thomas Henzler, Stefan O. Schoenberg

163    New TNM classification: achievements and hurdles

Peter Goldstraw

Treatment

172    A review of clinical practice guidelines for lung cancer

Jutta J. von Dincklage, David Ball, Gerard A. Silvestri

190    Customized chemotherapy in metastatic non-small cell lung cancer(NSCLC)

Jia Wei, Teresa Moran, Zhengyun Zou, Xiaoping Qian,Lifeng Wang, Carlos Camps, Wenjing Hu, Imane Chaib, Belén Sanchez, Lixia Xu,Niki Karachaliou, María Sanchez-Ronco, Baorui Liu, Rafael Rosell

199    Management of elderly patients

Alain Vergnenegre, Romain Corre, Hervé Lena, Hervé LeCaer

207    Alternative to surgery in early stage NSCLC—interventionalradiologic approaches

Kyungmouk Steve Lee, Bradley B. Pua

221    Supportive and palliative care for lung cancer patients

Patsy Yates, Penelope Schofield, Isabella Zhao, DavidCurrow

Surgery

227    Thoracoscopic sleeve resection—the better approach?

Calvin S.H. Ng

230    Surgery in 2013 and beyond

Rishendran Naidoo, Morgan N. Windsor, Peter Goldstraw

246    Management of ground-glass opacities: should all pulmonarylesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

256    Video-assisted thoracoscopic lobectomy—from an experimental therapyto the standard of care

Tristan D. Yan

258    Techniques of VATS lobectomy

John D. Mitchell

263    Contraindications of video-assisted thoracoscopic surgicallobectomy and determinants of conversion to open

Jennifer M. Hanna, Mark F. Berry, Thomas A. D’Amico

272    Current costs of video-assisted thoracic surgery (VATS) lobectomy

Tunc Lacin, Scott Swanson

276    Indication for VATS sublobar resections in early lung cancer

Antonio E. Martin-Ucar, Maria Delgado Roel

283    Totally thoracoscopic pulmonary anatomic segmentectomies: technical considerations

Dominique Gossot, Rym Zaimi, Ludovic Fournel, MadalinaGrigoroiu, Emmanuel Brian, Charles Neveu

291    Teaching video-assisted thoracic surgery (VATS) lobectomy

Philip W. Carrott Jr, David R. Jones

297    Right, middle, and lower bronchial sleeve lobectomy by videoassisted thoracic surgery

Xin Zhang, Gui-Lin Peng, Li-Xia Liang, Jian-Xing He

300    Non-intubated complete thoracoscopic bronchial sleeve resection for central lung cancer

Wenlong Shao, Kevin Phan, Xiaotong Guo, Jun Liu, QinglongDong, Jianxing He

304    Anesthesia with nontracheal intubation in thoracic surgery

Qinglong Dong, Lixia Liang, Yingfen Li, Jun Liu, WeiqiangYin, Hanzhang Chen, Xin Xu, Wenlong Shao, Jianxing He

310    Video-assisted thoracoscopic lobectomy for non-small cell lungcancer in patients with severe chronic obstructive pulmonary disease

Wei Wang, Zhiqiang Xu, Xinguo Xiong, Weiqiang Yin, XinXu, Wenlong Shao, Hanzhang Chen, Jianxing He

318    Analysis of feasibility and safety of complete video-assistedthoracoscopic resection of anatomic pulmonary segments under non-intubatedanesthesia

Zhihua Guo, Wenlong Shao, Weiqiang Yin, Hanzhang Chen,Xin Zhang, Qinglong Dong, Lixia Liang, Wei Wang, Guilin Peng, Jianxing He

326    Comparative study of systematic thoracoscopic lymphadenectomy andconventional thoracotomy in resectable non-small cell lung cancer

Wei Wang, Weiqiang Yin, Wenlong Shao, Gening Jiang, QunWang, Lunxu Liu, Deruo Liu, Zheng Wang, Zhihua Zhu, Hanzhang Chen, Jianxing He

Medical Oncology

333    Neoadjuvant chemotherapy in early-stage non-small cell lungcancer

Francesc Salvà, Enriqueta Felip

338    Adjuvant chemotherapy of completely resected early stage nonsmallcell lung cancer (NSCLC)

Ying Liang, Heather A. Wakelee

346    VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer

Xiuyi Zhi, Wen Gao, Baohui Han, Yue Yang, Hui Li, DeruoLiu, Changli Wang, Gong Min, Hao Long, James R. Rigas, Mark Carey, ThierryJahan, Amanda Sammann, Joseph Reza, Daoyuan Wang, Michael J. Mann, David M.Jablons, Jianxing He, for the China Clinical Trials Consortium

353    Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy

Charles A. Butts

361    Adjuvant molecularly targeted therapy—epidermal growth factortyrosine kinase inhibition and beyond

Joel W. Neal, Lecia V. Sequist

365    The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era

Zarnie Lwin, Jonathan W. Riess, David Gandara

375    Chemotherapy advances in small-cell lung cancer

Bryan A. Chan, Jermaine I. G. Coward

391    Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer

Peter Savas, Brett Hughes, Benjamin Solomon

408    Apoptotic agents

Dean A. Fennell

414    Adaptive resistance to targeted therapies in cancer

Rafael Rosell, Niki Karachaliou, DanielaMorales-Espinosa, Carlota Costa, Miguel Angel Molina, Irene Sansano, AmayaGasco, Santiago Viteri, Bartomeu Massuti, Jia Wei, María González Cao,Alejandro Martínez Bueno

Radiotherapy

422    State of the art of radiotherapy

Pilar Garrido, Mª Eugenia Olmedo

433    Recent advances in radiotherapy for thoracic tumours

Michael Fay, Christopher M. Poole, Gary Pratt

439    Alternatives to surgery in early stage disease—stereotactic bodyradiotherapy

Meredith Elana Giuliani, Andrea Bezjak

447    Post-operative radiation therapy

Amaury Paumier, Cécile Le Péchoux

457    Proton radiotherapy in the treatment of lung cancer

Heath Devin Skinner, Ritsuko Komaki

Prognosis

464    Prognostic and predictive biomarkers in early stage non-smallcell lung cancer: tumor based approaches including gene signatures

Simona Carnio, Silvia Novello, Mauro Papotti, MarcoLoiacono, Giorgio Vittorio Scagliotti

474    Prognostic and predictive biomarkers in early stage NSCLC: CTCsand serum/plasma markers

Philip A. J. Crosbie, Rajesh Shah, Yvonne Summers,Caroline Dive, Fiona Blackhall

490    Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

501    Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)

Laura Bonanno

513    Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Bartomeu Massuti, Jose Miguel Sanchez, FlorentinoHernando-Trancho, Niki Karachaliou, Rafael Rosell

527    Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients

Margarita Majem, Jordi Remon

539    EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, BalazsHalmos, Rom S. Leidner

544    International trial of adjuvant therapy in high risk stage Inonsquamous cell carcinoma identified by a 14-gene prognostic signature

Johannes R. Kratz, Michael J. Mann, David M. Jablons

548    Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advancednon-small-cell lung cancer: a meta-analysis

Wenhua Liang, Yaxiong Zhang, Shiyang Kang, Hui Pan,Wenlong Shao, Qiuhua Deng, Xiaoshun Shi, Wei Wang, Jianxing He

Translational Medicine

560    FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Hans-Ulrich Schildhaus, Lucia Nogova, Jürgen Wolf,Reinhard Buettner

569    ALK and ROS1 as a joint target for the treatment of lung cancer: a review

Raimon Puig de la Bellacasa, Niki Karachaliou, RogerEstrada-Tejedor, Jordi Teixidó, Carlota Costa, José I. Borrell

584    Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Marc Bos, Masyar Gardizi, Hans-Ulrich Schildhaus,Reinhard Buettner, Juergen Wolf

594    HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

Ana Christina Garrido-Castro, Enriqueta Felip

600    Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)

Teresa Morán, Vanesa Quiroga, María de los Llanos Gil, LaiaVilà, Nuria Pardo, Enric Carcereny, Laia Capdevila,
Ana M. Muñoz-Mármol, Rafael Rosell

614    KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

624    The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung

Niki Karachaliou, Rafael Rosell, Santiago Viteri

632    Inhibition of insulin-like growth factor receptor: end of atargeted therapy?

Rathi N. Pillai, Suresh S. Ramalingam

641    MET inhibition in lung cancer

Jessica Menis, Matteo Giaj Levra, Silvia Novello

658    Irreversible EGFR-TKIs: dreaming perfection

Lorenza Landi, Federico Cappuzzo

Take a view at the book: Lung Cancer